Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir + Peg-IFN + RBV in Treatment-Naive Non-Cirrhotic HCV GT1
NCT03020004Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of danoprevir in hepatitis C (HCV), sponsored by Ascletis Pharma Inc.. Started Jan 2016; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03020004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020004.